Wenjing Zhou
Uppsala, C, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 16, 2025
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Journal: Nature communications
Published: September 05, 2019
AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 09, 2019
Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Journal: Nature communications
Published: September 17, 2018
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 16, 2018
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort.
Journal: International journal of breast cancer
Published: October 04, 2016
Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.
Journal: International journal of breast cancer
Published: May 12, 2014
The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Journal: Annals of surgical oncology
Published: October 20, 2013
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.
Journal: International journal of breast cancer
Published: September 18, 2013
Last Updated: 09/26/2026